IONIS

Akcea Therapeutics, Inc. is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., the leader in RNA therapeutics. Akcea commercializes TEGSEDI® (inotersen), which is available in the E.U. and Brazil, and WAYLIVRA® (volanesorsen), which is available in the E.U... In 2020, Ionis leadership made the bold decision to shift the company to directly serving patients by launching our products independently as a fully integrated biotechnology company. In the course of just a few years, we've built a wholly owned, rich, late stage pipeline of potentially life-changing RNA-targeted medicines for people in critical need of significant advances, particularly in our focus areas of neurology and cardiology. We also continue to engage with partners on promising programs outside of our core areas of focus to advance investigational medicines for patients in other therapeutic areas with high need... We are at an exciting time in Ionis' trajectory as we prepare to launch our first wholly owned..

Also known as: Ionis Pharmaceuticals, Ionis Pharmaceuticals, Inc.

Primary location: Carlsbad United States